Houston, TX – Jan 21-25, 2017 – 53rd STS Annual Meeting
BioStable Science & Engineering will be at the 53rd STS Annual Meeting of the Society of Thoracic Surgeons from January 21 – 25, 2017 in Houston, TX at booth 819.
BioStable De Novo Application to FDA for the HAART 300
BioStable Science & Engineering, Inc. announced today that it has completed a direct de novo application to the U.S. Food and Drug Administration (FDA) for Class II designation of the HAART 300 Aortic Annuloplasty Device.
Barcelona, Spain – Oct 1-5, 2016 – 30th EACTS Annual Meeting
BioStable Science & Engineering will be at the 30th EACTS Annual Meeting of European Association for Cardio-Thoracic Surgery from October 1-5, 2016 in Barcelona, Spain.
European Commercialization of the BioStable HAART 300
BioStable Science & Engineering, Inc. announced today that the first commercial implantation of its HAART 300 Aortic Annuloplasty Device was performed by Dr. Domenico Mazzitelli on Wednesday May 11th at the German Heart Center Munich.
BioStable HAART 300 Receives CE Mark Approval
BioStable Science & Engineering, Inc. announced today the company has received CE Mark approval for the HAART 300 Aortic Annuloplasty Device, the first commercially available internal aortic annuloplasty ring for aortic valve repair.